

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: O. Kamoda, et al

SERIAL NO.: Not yet assigned n
(Continuation of 09/721,182) GROUP: Not yet assigned

FILED: July 18, 2003 EXAMINER: Not yet assigned

FOR: GUANIDINOMETHYL CYCLOHEXANE CARBOXYLIC ACID ESTER
DERIVATIVES

**Mail Stop: New Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as "Express Mail Post Office To Addressee," Express Mailing Label No. EV343734404US in an envelope addressed to the Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on July 18, 2003

By: Michelle P. Chicos
Michelle P. Chicos

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. **LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION**

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. **COPIES**

- a. Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)

- a. Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).
- b. A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:
- c. The following additional information is provided for the Examiner's consideration:

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)
(check one box)

- a. within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.
- b. within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.
- c. before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e)below, or, if no certification has been made, charge our deposit account a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):
(check one box)

- before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).
 - a. No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).

or
 - b. See the certification below. No fee is required.

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby certifies that

- a. each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- b. no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.
- c. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

- Please charge Deposit Account No. 04-1105 in the amount of \$ _____ for the above-indicated fee. A triplicate copy of this paper is attached.
- No fee is required.
- Fee enclosed, check in the amount of \$ 180.00.

Applicants: A. Rosowsky
Page 4

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 04-1105.

Respectfully submitted,



John B. Alexander (Reg. No. 48,399)
EDWARDS & ANGELL, LLP
P. O. Box 9169
Boston, MA 02209

July 18, 2003

Tel. No. (617) 439-4444

FORM PTO-1449		ATTY DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT		47216-DIV CON	T Be Assigned
APPLICANT(S)			
O. KAMODA, et al.			
FILING DATE		GROUP NO.	
July 18, 2003		To Be Assigned	

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA ✓	4,348,410	9/7/82	Muramatsu et al.	424	309	
	AB ✓	4,465,851	8/1984	Muramatsu, et al.	560	125	
	AC ✓	4,798,680	1/7/89	Nohira, et al.	252	299	
	AD ✓	4,844,835	1/4/89	Uchida, et al.	252	299	
	AE ✓	2,584,160	2/5/52	Sahyun, et al.	260	474	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
	BA	0 585 130 A2	2/1994	EP			
	BB	2 058 773	4/1981	United Kingdom			
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

CA	The Organic Chemistry of Drug Design and Drug Action, pages 15-22, Silverman
CB	Jones et al., "Synthesis of Smectic Liquid-Crystalline Polysiloxanes from Biphenylcarboxylate Esters and Their Use as Stationary Phases for High-Resolution Gas Chromotography" Journal of Organic Chemistry, vol. 49, no. 25, 1984, pages 4947-51.
CC	Kitazume et al., "Design and Synthesis of New Fluorinated Ferroelectric Liquid Crystalline Polymers" Journal of the American Chemical Society, vol. 12, no. 18, 1990, pages 6608-15.
CD	Hirota et al., "Pyramidine Derivatives and Related Compounds. 39. A Novel Cycloaromatization reaction of 5-Formyl-1,3-dimethyluracil with Three-Carbon Nucleophiles. Synthesis of Substituted 4-Hydroxybenzoates" Journal of Organic Chemistry, vol. 46, no. 20, 1981, pages 3949-53.
CE	Nakajima et al., "Preparation of 3-phenylsalicylamide Derivatives" J. Pharm Soc. Japan, vol. 76, 1956, pages 1211-13.

EXAMINER:

DATE: